“CS had a cultural problem that translated into a lack of accountability,” Finma President Marlene Amstad told the Sunday newspaper. “Often it was not clear who was responsible for what. This favored a negligent handling of risks.” Whether to start fresh proceedings remains an “open question,” she said, adding, “we’re not a law enforcement agency, but we’re exploring options.”
Symbiotec Pharmalab sets price band for Rs 1,757 crore IPO, to open on August 24
Symbiotec Pharmalab will launch its ₹1,757-crore IPO from August 24–27, 2026, with a price band of ₹938–988 per share. The minimum bid is 15 shares,
August 19, 2026